Prescription medicine
Insulin lispro Brand names: Humalog, Lyumjev, Admelog
Insulin lispro (Humalog) is a prescription medicine with an FDA approval on record since 2017. No generic is listed; pharmacies paid $10.19 per mL (Insulin lispro 100 unit/mL kwikpen) in the October 7, 2026 NADAC survey.
- No generic listed
- A presentation discontinued
Check it at the source: the insulin lispro FDA label on DailyMed (effective June 4, 2025, Sanofi-Aventis U.S. LLC); the BLA 209196 record on Drugs@FDA; every insulin lispro label on DailyMed.
Highlights of the record
FDA label of June 4, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageADMELOG is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.
Forms and strengths
Injection (solution); injection (suspension).
On the market
- Earliest approval on file
- December 11, 2017 Admelog, Sanofi-Aventis Us; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 4 of which 0 under generic applications, 4 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $10.19 per mL Insulin lispro 100 unit/mL kwikpen
- Shortage (FDA)
- None current 4 past records
- Recalls by its makers (FDA)
- 4 since 2018 1 Class I among all firms' recalls; latest March 12, 2024
- FAERS reports
- 139,157 through July 30, 2026
What is insulin lispro used for?
From the label: indications and usageADMELOG is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. ADMELOG is a rapid-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.
Conditions named in the indications of insulin lispro's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Insulin Analog.
Source: FDA drug label (ADMELOG), Sanofi-Aventis U.S. LLC, effective June 4, 2025 (SPL set 0691def8-4a7b-4de3-866f-a280989f47f1), via openFDA; the full label on DailyMed
What does the patient leaflet for insulin lispro say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What should I avoid while using ADMELOG?While using ADMELOG do not: drive or operate heavy machinery, until you know how ADMELOG affects you. drink alcohol or use prescription or over-the-counter medicines that contain alcohol.
Source: FDA drug label (ADMELOG), Sanofi-Aventis U.S. LLC, effective June 4, 2025 (SPL set 0691def8-4a7b-4de3-866f-a280989f47f1), via openFDA; the full label on DailyMed
Is there a generic for insulin lispro (Humalog)?
No generic insulin lispro is approved (Drugs@FDA, October 8, 2026).
- 2017 earliest approval on file
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for insulin lispro (Humalog)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $10.19 per mL (Insulin lispro 100 unit/mL kwikpen), about the same as a year earlier. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Insulin lispro 100 unit/mL vial (generic)
- Admelog 100 unit/mL vial (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Insulin lispro 100 unit/mL kwikpen | Generic | $10.19 per mL | n/a | no change |
| Insulin lispro 100 unit/mL vial | Generic | $2.40 per mL | n/a | no change |
| Insulin lispro jr 100 unit/mL kwikpen | Generic | $10.20 per mL | n/a | +0.1% |
| Insulin lispro mix 75-25 kwkpn | Generic | $10.21 per mL | n/a | no change |
| Admelog 100 unit/mL vial | Brand | $10.98 per mL | n/a | -0.2% |
| Admelog solostar 100 unit/mL | Brand | $12.11 per mL | n/a | no change |
| Humalog 100 unit/mL cartridge | Brand | $9.79 per mL | n/a | +0.1% |
| Humalog 100 unit/mL kwikpen | Brand | $10.17 per mL | n/a | no change |
| Humalog 100 unit/mL vial | Brand | $6.36 per mL | n/a | no change |
| Humalog 200 unit/mL kwikpen | Brand | $20.31 per mL | n/a | -70% |
| Humalog jr 100 unit/mL kwikpen | Brand | $10.16 per mL | n/a | no change |
| Humalog mix 50-50 kwikpen | Brand | $10.14 per mL | n/a | -0.1% |
| Humalog mix 75-25 kwikpen | Brand | $10.17 per mL | n/a | no change |
| Humalog mix 75-25 vial | Brand | $8.15 per mL | n/a | -0.1% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Is insulin lispro in shortage?
No insulin lispro presentation is listed as in shortage in the FDA Drug Shortage Database (read October 8, 2026); its 4 records are all marked to be discontinued, the latest updated September 1, 2026. ASHP keeps a separate shortage list, which can differ.
| Presentation | Company | Status | Updated |
|---|---|---|---|
| Humalog Mix 75/25, Injection, 100 [iU]/1 mL (NDC 0002-8233-05) | Eli Lilly and Co. | To Be Discontinued | September 1, 2026 |
| Insulin Lispro Junior KwikPen, Injection, 100 [iU]/1 mL (NDC 0002-7752-05) | Eli Lilly and Co. | To Be Discontinued | September 1, 2026 |
| Lyumjev, Injection, U-100 Tempo Pen (NDC 0002-8235-05) | Eli Lilly and Co. | To Be Discontinued | October 24, 2025 |
| Lyumjev, Injection, U-100 Tempo Pen Sample (NDC 0002-8235-99) | Eli Lilly and Co. | To Be Discontinued | October 24, 2025 |
Every insulin lispro presentation in the FDA shortage database
Source: FDA Drug Shortage Database via openFDA, updated October 8, 2026
Has insulin lispro been recalled?
The FDA's Enforcement Report lists 4 recalls naming insulin lispro since 2018: 1 Class I (the most serious), 3 Class II, 0 Class III; 2 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| March 12, 2024 | Class II | Eli Lilly & Company | CGMP Deviations |
| April 11, 2023 | Class II | Sanofi-Aventis U.S. LLC | Lack of Assurance of Sterility: Malformed crimped collar seal |
| April 5, 2022 | Class I | Cardinal Health Inc. | TEMPERATURE ABUSE: Products were exposed to temperatures outside of the products labeled storage conditions due to inclement weather. |
| July 5, 2018 | Class II | Sanofi-Aventis U.S. LLC | Temperature Abuse: Product samples of Admelog may not have been shipped at proper temperature. |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the insulin lispro label say about other medicines?
The insulin lispro label names 17 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Albuterol | drug interactions | … progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when ADMELOG is concomitantly administered with these drugs. |
| Clonidine | drug interactions | Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of ADMELOG Drugs: Alcohol, beta-blockers, clonidine, and lithium salts. |
| Clozapine | drug interactions | Drugs That May Decrease the Blood Glucose Lowering Effect of ADMELOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors … |
| Danazol | drug interactions | Drugs That May Decrease the Blood Glucose Lowering Effect of ADMELOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors … |
| Disopyramide | drug interactions | Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. … |
| Epinephrine | drug interactions | … (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when ADMELOG is concomitantly administered with these drugs. |
| Fluoxetine | drug interactions | Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. … |
| Glucagon | drug interactions | Drugs That May Decrease the Blood Glucose Lowering Effect of ADMELOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors … |
| Isoniazid | drug interactions | Drugs That May Decrease the Blood Glucose Lowering Effect of ADMELOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors … |
| Lithium | drug interactions | Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of ADMELOG Drugs: Alcohol, beta-blockers, clonidine, and lithium salts. |
| Niacin | drug interactions | Drugs That May Decrease the Blood Glucose Lowering Effect of ADMELOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors … |
| Octreotide | drug interactions | Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. … |
| Olanzapine | drug interactions | Drugs That May Decrease the Blood Glucose Lowering Effect of ADMELOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors … |
| Pentoxifylline | drug interactions | Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. … |
Every other medicine the insulin lispro label names
| Medicine named | Section | What the label says |
|---|---|---|
| Pramlintide | drug interactions | … fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. … |
| Somatropin | drug interactions | … progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. … |
| Terbutaline | drug interactions | … somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when … |
Source: FDA drug label (ADMELOG), Sanofi-Aventis U.S. LLC, effective June 4, 2025 (SPL set 0691def8-4a7b-4de3-866f-a280989f47f1), via openFDA; the full label on DailyMed
What do FAERS reports show for insulin lispro?
The FDA Adverse Event Reporting System holds 139,157 reports that list insulin lispro among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 6,059 are coded as a death and 34,351 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as insulin lispro?
14 other medicines are given the same way (subcutaneous) and in the same FDA class as insulin lispro or labeled mainly for the same use (type 2 diabetes), the same class first. Type 2 diabetes lists all 52 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (subcutaneous) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Insulin glargine | Type 2 diabetes, Type 1 diabetes | none listed | $2.90 per mL 100 pen | A presentation being discontinued |
| Insulin aspart | Type 2 diabetes, Type 1 diabetes | none listed | $6.95 per mL 100 unit/mL vial | No current entry |
| Insulin degludec | Type 2 diabetes, Type 1 diabetes | none listed | $11.39 per mL 100 unit/mL pen | No current entry |
| Insulin detemir | Type 2 diabetes, Type 1 diabetes | none listed | n/a | No current entry |
| Insulin glulisine | Type 2 diabetes, Type 1 diabetes | none listed | $8.16 per mL 100 unit/mL vial | No current entry |
| Insulin degludec and liraglutide | Type 2 diabetes | none listed | $85.89 per mL 100 unit-3.6 mg/mL pen | No current entry |
| Insulin glargine and lixisenatide | Type 2 diabetes | none listed | $57.06 per mL 100 unit-33 mcg/mL pen | No current entry |
| Tirzepatide | Type 2 diabetes | none listed | $538.68 per mL 10 mg/0.5 mL pen | No current entry |
Every medicine labeled for the same conditions as insulin lispro
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
How does insulin lispro compare with medicines for the same use?
3 side-by-side pages set insulin lispro beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.
What next?
- Alternatives to insulin lispro
- 14 medicines for the same use
- Other insulin analogs
- the pharmacologic class, with prices and generics
- Insulin lispro side effects
- the label's list beside FAERS reports
- Insulin lispro shortage record
- every presentation, company and date
- Check an interaction
- what two or more labels say about each other